GTGann Ting

Gann Ting

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gann Ting has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Translating Research for the Radiotheranostics of Nanotargeted 188Re-Liposome

    by Chih-Hsien Chang, Ming-Cheng Chang, Ya-Jen Chang, Liang-Cheng Chen, Te-Wei Lee, Gann Ting

    Nanoliposomes are one of the leading potential nano drug delivery systems capable of targeting chemotherapeutics to tumor sites because of their passive nano-targeting capability through the enhanced permeability and retention (EPR) effect for cancer patients. Recent advances in nano-delivery systems have inspired the development of a wide range of nanotargeted materials and strategies for applications in preclinical and clinical usage in the cancer field. Nanotargeted 188Re-liposome is a unique internal passive radiotheranostic agent for nuclear imaging and radiotherapeutic applications in various types of cancer. This article reviews and summarizes our multi-institute, multidiscipline, and multi-functional studied results and achievements in the research and development of nanotargeted 188Re-liposome from preclinical cells and animal models to translational clinical investigations, including radionuclide nanoliposome formulation, targeted nuclear imaging, biodistribution, pharmacokinetics, radiation dosimetry, radiation tumor killing effects in animal models, nanotargeted radionuclide and radio/chemo-combination therapeutic effects, and acute toxicity in various tumor animal models. The systemic preclinical and clinical studied results suggest 188Re-liposome is feasible and promising for in vivo passive nanotargeted radionuclide theranostics in future cancer care applications.


  • Open Access

    A phase 0 study of the pharmacokinetics, biodistribution, and dosimetry of 188Re-liposome in patients with metastatic tumors

    by Shyh-Jen Wang, Wen-Sheng Huang, Chi-Mu Chuang, Chih-Hsien Chang, Te-Wei Lee, Gann Ting, Ming-Huang Chen, Peter Mu-Hsin Chang, Ta-Chung Chao, Hao-Wei Teng, et al.

    Liposomes are drug nano-carriers that are capable of targeting therapeutics to tumor sites because of enhanced permeability retention (EPR). In several preclinical studies with various tumor-bearing mice models, 188Re-liposome that has been developed by the Institute of Nuclear Energy Research (INER) demonstrates favorable in vivo tumor targeting, biodistribution, pharmacokinetics, and dosimetry. It inhibits the growth of tumors, increased survival, demonstrates good synergistic combination, and was safe to use. This study conducts a phase 0 low-radioactivity clinical trial of nano-targeted radiotherapeutics 188Re-liposome to evaluate the effectiveness with which it targets tumors and the pharmacokinetics, biodistribution, dosimetry, and its safety in use. Twelve patients with metastatic cancers are studied in this trial. Serial whole-body scans and SPECT/CT are taken at 1, 4, 8, 24, 48, and 72 h after intravenous injection of 111 MBq of 188Re-liposome. The effectiveness with which tumors are targeted, the pharmacokinetics, biodistribution, dosimetry, and safety are evaluated using the VelocityAI and OLINDA/EXM software. Blood samples are collected at different time points for a pharmacokinetics study and a safety evaluation that involves monitoring changes in liver, renal, and hematological functions. The T½z for 188Re-liposome in blood and plasma are 36.73 ± 14.00 h and 52.02 ± 45.21 h, respectively. The doses of radiation that are absorbed to vital organs such as the liver, spleen, lung, kidney, and bone marrow are 0.92 ± 0.35, 1.38 ± 1.81, 0.58 ± 0.28, 0.32 ± 0.09, and 0.06 ± 0.01 mGy/MBq, respectively, which is far less than the reference maximum tolerance dose after injection of 188Re-liposome. 188Re-liposome is absorbed by metastatic tumor lesions and the normal reticuloendothelial (RES) system. Certain patients exhibit a therapeutic response. This phase 0 exploratory IND study shows that nanocarrier 188Re-liposome achieves favorable tumor accumulation and tumor to normal organ uptake ratios for a subset of cancer patients. The clinical pharmacokinetic, biodistribution, and dosimetry results justify a further dose-escalating phase 1 clinical trial. Taiwan FDA MA1101G0 (Jan 31, 2012).


  • Dosimetric evaluation of nanotargeted 188Re-liposome with the MIRDOSE3 and OLINDA/EXM programs

    by Chih-Hsien Chang, Ya-Jen Chang, Te-Wei Lee, Gann Ting, Kwo-Ping Chang


  • Open Access

    Nanotargeted Radionuclides for Cancer Nuclear Imaging and Internal Radiotherapy

    by Gann Ting, Chih-Hsien Chang, Hsin-Ell Wang, Te-Wei Lee

    Current progress in nanomedicine has exploited the possibility of designing tumor-targeted nanocarriers being able to deliver radionuclide payloads in a site or molecular selective manner to improve the efficacy and safety of cancer imaging and therapy. Radionuclides of auger electron-,α-,β-, andγ-radiation emitters have been surface-bioconjugated or after-loaded in nanoparticles to improve the efficacy and reduce the toxicity of cancer imaging and therapy in preclinical and clinical studies. This article provides a brief overview of current status of applications, advantages, problems, up-to-date research and development, and future prospects of nanotargeted radionuclides in cancer nuclear imaging and radiotherapy. Passive and active nanotargeting delivery of radionuclides with illustrating examples for tumor imaging and therapy are reviewed and summarized. Research on combing different modes of selective delivery of radionuclides through nanocarriers targeted delivery for tumor imaging and therapy offers the new possibility of large increases in cancer diagnostic efficacy and therapeutic index. However, further efforts and challenges in preclinical and clinical efficacy and toxicity studies are required to translate those advanced technologies to the clinical applications for cancer patients.


    • 1 January 2010
      • Vol. 30  (1) , 65-72

    MicroSPECT/CT imaging and pharmacokinetics of 188Re-(DXR)-liposome in human colorectal adenocarcinoma-bearing mice.

    by Min-Hua Chen, Chih-Hsien Chang, Ya-Jen Chang, Liang-Cheng Chen, Chia-Yu Yu, Yu-Hsien Wu, Wan-Chi Lee, Chung-Hsin Yeh, Feng-Huei Lin, Te-Wei Lee, et al.

    Nanoliposome can be designed as a drug delivery carrier to improve the pharmacological and therapeutic properties of drug administration. (188)Re-labeled nanoliposomes are useful for diagnostic imaging as well as for targeted radionuclide therapy. In this study, the in vivo nuclear imaging, pharmacokinetics and biodistribution of administered nanoliposomes were investigated as drug and radionuclide carriers for targeting solid tumor via intravenous (i.v.) administration. The radiotherapeutics ((188)Re-liposome) and radiochemotherapeutics ((188)Re-DXR-liposome) were i.v. administered to nude mice bearing human HT-29 colorectal adenocarcinoma xenografts. (188)Re-liposome and (188)Re-DXR-liposomes show similar biodistribution profile; both have higher tumor uptake, higher blood retention time, and lower excretion rate than (188)Re-N,N-bis(2-mercaptoethyl)-N',N'-diethylenediamine (BMEDA). In contrast to tumor uptake, the area under the curve (AUC) value of tumor for (188)Re-liposome and (188)Re-DXR-liposome was 16.5- and 11.5-fold higher than that of free (188)Re-BMEDA, respectively. Additionally, (188)Re-liposome and (188)Re-DXR-liposome had a higher tumor-to-muscle ratio at 24 h (14.4+/-2 .7 and 17.14+/-4.1, respectively) than (188)Re-BMEDA (1.6+/-0.1). The tumor targeting and distribution of (188)Re-(DXR)-liposome (representing (188)Re-DXR-liposome and (188)Re-liposome) can also be acquired by signal photon-emission computed tomography/computed tomography images as well as whole body autoradiograph. These results suggest that (188)Re-(DXR)-liposomes are potentially promising agents for passive targeting treatment of malignant disease.


    • 1 October 2009
      • Vol. 29  (10) , 4107-18

    Cancer nanotargeted radiopharmaceuticals for tumor imaging and therapy.

    by Gann Ting, Chih-Hsien Chang, Hsin-Ell Wang

    Cancer is the second leading cause of death in the world. Radiolabeled nanocarriers or nanoparticles can be designed and used for cancer diagnostic and therapeutic purposes when tagged with appropriate radionuclides. Current progress in nanotechnology and nanomedicine has exploited the possibility of designing tumor-targeted nanocarriers able to deliver radionuclide payloads in a selective manner to improve the efficacy and safety of cancer imaging and therapy. The major nanocarriers include liposomes, dendrimers, quantum dots, iron oxide and carbon nanotubes. In addition, the combining of tumor specific multifunctional and multimodality nanocarriers will hopefully achieve earlier tumor detection and better tumor treatment. Several radiolabeled multifunctional and multimodality nanoparticles have been effectively demonstrated in detecting and treating cancer in animal models. However, further preclinical and clinical efficacy and toxicity studies are required to translate these advanced technologies to the health care of cancer patients. The aim of this article is to provide a brief overview of current status of applications, advantages and up-to-date research and development of nanotargeted radiopharmaceuticals in cancer imaging and therapy.


    • 19 August 2007
      • Vol. 27, 2217-25

    Biodistribution, pharmacokinetics and microSPECT/CT imaging of 188Re-bMEDA-liposome in a C26 murine colon carcinoma solid tumor animal model.

    by Ya-Jen Chang, Chih-Hsien Chang, Tsui-Jung Chang, Chia-Yu Yu, Liang-Cheng Chen, Meei-Lin Jan, Tsai-Yueh Luo, Te-Wei Lee, Gann Ting

    Nanoliposomes are useful carriers in drug delivery. Radiolabeled nanoliposomes have potential applications in radiotherapy and diagnostic imaging. In this study, the biodistribution and pharmacokinetics of 188Re-BMEDA-labelled pegylated liposomes (RBLPL) and unencapsulated 188Re-BMEDA administered by the i.v. route in murine C26-colon tumour-bearing mice were investigated. MicroSPECT/CT images were performed to evaluate the distribution and tumor targeting of RBLPL in mice. For the biodistribution study, the highest uptake of liposome in tumors was 3.62% +/- 0.73% at 24 h after RBLPL administration, and the tumor to muscle ratio of RBLPL was 7.1-fold higher than that of 188Re-BMEDA. With image analysis, the highest SUV in tumor was 2.81 +/- 0.26 at 24 h after injection of RBLPL. The Pearson correlation analysis showed a positive correlation of tumor targeting or uptake of RBLPL between biodistribution and microSPECT semi-quantification imaging analysis (r = 0.633). The results of the pharmacokinetics revealed that the area under the tissue concentration-time curve (AUC) of RBLPL was 4.7-fold higher than that of unencapsulated 188Re-BMEDA. These results suggested the potential benefit and advantage of 188Re-labeled nanoliposomes for imaging and treatment of malignant diseases.


  • Study on the Separation of Carrier-Free Yttrium-90 from Strontium-90

    by Te-Wei Lee, Gann Ting

    The separation of carrier-free 90Y from 90Sr by solvent extraction with di-(2-ethylhexyl) phosphoric acid (HDEHP) in dodecane has been investigated in this study. The extraction equilibrium time, the effect of temperature, concentration of extractant, and hydrochloric acid concentration on this extraction system were examined. Based on the studies, the chemical procedure for the separation of carrier-free 90 Y from its parent 90Sr have been established. The chemical yield of 90Y is about 80%. Meanwhile, the 90Sr impurity is less than 1×10−6% and the trace of extractant presented in the final product can be removed by fumed with HNO3. Consequently, the preparation of millicurie of 90Y is quite satisfactory for the adsorption in microsphere resin for radiotherapy applications.


  • Extraction of Uranium(VI) from Phosphoric Acid by Mono-(2-Ethylhexyl) Phosphoric Acid and Neutral Organophosphorus Synergist in Kerosene Diluent

    by Gann Ting, Te-Wei Lee

    Article Extraction of Uranium(VI) from Phosphoric Acid by Mono-(2-Ethylhexyl) Phosphoric Acid and Neutral Organophosphorus Synergist in Kerosene Diluent was published on February 1, 1981 in the journal Radiochimica Acta (volume 28, issue 2).